Impact of tislelizumab plus chemotherapy versus placebo plus chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of the RATIONALE-306 trial.

被引：0

作者：

Yoon, Harry H.

Xu, Jianming

Kato, Ken

Pan, Yueyin

Park, Sook Ryun

Shen, Lin

Van Cutsem, Eric

Jimenez-Fonseca, Paula

Barnes, Frederick

Sun, Tianmo

Barnes, Gisoo

Victor, Timothy

机构：

[1] Mayo Clin Rochester, Rochester, MN USA

[2] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China

[3] Natl Canc Ctr Hosp, Dept Head & Neck Esophageal Med Oncol, Chuo City, Tokyo, Japan

[4] Anhui Prov Hosp, Hefei, Anhui, Peoples R China

[5] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[6] Beijing Canc Hosp, Beijing, Peoples R China

[7] Fdn Med Inc, Cambridge, MA USA

[8] Cent Univ Hosp Asturias, ISPA, Oviedo, Spain

[9] BeiGene USA Inc, San Mateo, CA USA

[10] BeiGene Beijing Co Ltd, Beijing, Peoples R China

来源：

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.366

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：366 / 366

页数：1

共 21 条